Back to Top
Brayton Purcell LLP
Call for A Free Consultation
800-598-0314
Nationwide Service for over 30 years

Dangerous Medications Archives

Partner Post: Risperdal Anti-Psychotic Drug Settlement

$2.2 Billion Risperdal Anti-Psychotic Drug Settlement  Written by James P. Nevin   Janssen, part of the well-known Johnson & Johnson company, pled guilty to misbranding its anti-psychotic medication Risperdal in a $2.2 billion dollar settlement. The company entered a guilty plea to one misdemeanor ending a complex legal case spanning...

Recall on GranuFlo and Naturalyte

On March 29, 2012, the Federal Drug Administration (FDA) recalled Granuflo, a powder acid concentrate, and Naturalyte, a liquid acid concentrate. Both products had been linked to cardiopulmonary arrests in dialysis patients. GranuFlo and Naturalyte were manufactured and distributed between January 2008 through June 2012 to Fresenius Medical Care North...

Johnson & Johnson settles Risperdal suit

Johnson & Johnson's agrees to a $181 million settlment with 36 states and the District of Columbia over Risperdal, an antipsychotic drug used off label by elderly and children to help with bipolar disorders. The settlement comes after prosecuters said that Johnson and Johnson's pharmaceutical subsidiary Janssen failed to disclose...

Bayer Opts to Settle Trasylol® Suits on Case by Case Basis

Bayer's Settlement Framework Weighs Each Suit on Several Factors November 2, 2010 -- To date, Bayer has settled approximately 200 of the 2,000 cases against it over the drug Trasylol, used to control bleeding during heart surgeries. Rather than settlements based on a universal point system stemming from either bellwether...

Fosamax® Lawsuit Ends in Mistrial

Mistrial Declared in First Fosamax® Lawsuit Against Merck September 14, 2009 -- The first trial against Merck over the osteoporosis drug Fosamax® ended in a mistrial Friday, September 11. The jurors had the case since September 2nd and were unable to come to a unanimous decision on whether Fosamax® caused...

Avandia® Study Shows Increase in Death Rate & Heart Attack

Avandia® (rosiglitazone)--Are Marginal Benefits Worth the Risk? December 22, 2008 -- The most recent study on Avandia®, released November 24, 2008, found death rates were 15 percent higher among patients treated with diabetes drug rosiglitazone (Avandia®), compared to those taking pioglitazone (Actos®), and the incidence of congestive heart failure was...

Medical Device Lawsuits & Ensuring Product Safety

Manufacturers of Unsafe Products Shielded by Supreme Court Ruling WASHINGTON, DC -- March 6, 2008 -- The Supreme Court ruled in favor of limiting lawsuits on product liability. It will now be difficult for individuals to sue faulty medical products that have been approved by the U.S. Food and Drug...

New Warning Label for Avandia Recommended by FDA

FDA Panel Recommends Warning Label for Avandia® WASHINGTON, DC -- August 3, 2007 -- A strong warning about heart attack risk should be added to the prescribing instructions for the diabetes drug Avandia® (rosiglitazone), according to an advisory panel to the Food and Drug Administration (FDA). Although the vote was...

Heart Attack, Heart Failure Reports Linked to Avandia

FDA Receives More Reports of Avandia® Side Effects WASHINGTON, DC -- July 20, 2007 -- The Food and Drug Administration (FDA) has seen a sharp increase in reports of heart attacks among patients who use the diabetes drug, Avandia®, since a medical journal article connected the drug to heart problems....

FDA Warning for Avandia Health Risks

Was the FDA Negligent in Overseeing the Diabetes Drug, Avandia®? WASHINGTON, DC -- June 22, 2007 --The Food and Drug Administration (FDA) may have been too hasty in approving the diabetes drug, Avandia®, and negligent in issuing timely warnings about its safety, according to some participants at a recent hearing...